Abstract
The three isotypes of peroxisome proliferator-activated receptors (PPARs), PPARa, β/δ and γ, are ligand-inducible transcription factors that belong to the nuclear hormone receptor family. PPARs are implicated in the control of inflammatory responses and in energy homeostasis and thus, can be defined as metabolic and anti-inflammatory transcription factors. They exert their anti-inflammatory effects by inhibiting the induction of pro-inflammatory cytokines, adhesion molecules and extracellular matrix proteins or by stimulating the production of anti-inflammatory molecules. Furthermore, PPARs modulate the proliferation, differentiation and survival of immune cells including macrophages, B cells and T cells. This review discusses the molecular mechanisms by which PPARs and their ligands modulate the inflammatory response. In addition, it presents recent developments implicating PPAR specific ligands in potential treatments of inflammationrelated diseases, such as atherosclerosis, inflammatory bowel diseases, Parkinsons and Alzheimers diseases.
Keywords: peroxisome proliferator-activated receptors, transcription factors, molecular mechanisms, inflammatory cells, inflammatory diseases, atherosclerosis, fibrosis, cancer
Current Medicinal Chemistry
Title: PPARs in Diseases: Control Mechanisms of Inflammation
Volume: 12 Issue: 25
Author(s): Radina Kostadinova, Walter Wahli and Liliane Michalik
Affiliation:
Keywords: peroxisome proliferator-activated receptors, transcription factors, molecular mechanisms, inflammatory cells, inflammatory diseases, atherosclerosis, fibrosis, cancer
Abstract: The three isotypes of peroxisome proliferator-activated receptors (PPARs), PPARa, β/δ and γ, are ligand-inducible transcription factors that belong to the nuclear hormone receptor family. PPARs are implicated in the control of inflammatory responses and in energy homeostasis and thus, can be defined as metabolic and anti-inflammatory transcription factors. They exert their anti-inflammatory effects by inhibiting the induction of pro-inflammatory cytokines, adhesion molecules and extracellular matrix proteins or by stimulating the production of anti-inflammatory molecules. Furthermore, PPARs modulate the proliferation, differentiation and survival of immune cells including macrophages, B cells and T cells. This review discusses the molecular mechanisms by which PPARs and their ligands modulate the inflammatory response. In addition, it presents recent developments implicating PPAR specific ligands in potential treatments of inflammationrelated diseases, such as atherosclerosis, inflammatory bowel diseases, Parkinsons and Alzheimers diseases.
Export Options
About this article
Cite this article as:
Kostadinova Radina, Wahli Walter and Michalik Liliane, PPARs in Diseases: Control Mechanisms of Inflammation, Current Medicinal Chemistry 2005; 12 (25) . https://dx.doi.org/10.2174/092986705774462905
DOI https://dx.doi.org/10.2174/092986705774462905 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Approaches to the Modulation of the Cyclooxygenase-2 and 5-Lipoxygenase Pathways
Current Topics in Medicinal Chemistry The Potential Therapeutic Value of Renin-Angiotensin System Inhibitors in the Treatment of Colorectal Cancer
Current Pharmaceutical Design Nanocellulose-based Delivery Systems and Cervical Cancer: Review of the Literature
Current Pharmaceutical Design Chronopharmaceutics Based Modern Colon Specific Drug Delivery Systems
Current Drug Discovery Technologies Platelet Toll-Like Receptor Expression: The Link Between “Danger” Ligands and Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) Editorial (Thematic Issue: From Nuisance to State-of-the-Art: FDG-PET/CT Imaging of Infection and Inflammation)
Current Molecular Imaging (Discontinued) Beneficial Actions of Polyunsaturated Fatty Acids in Cardiovascular Diseases: But, How and Why?
Current Nutrition & Food Science Cell Therapies for IBD: What Works?
Current Drug Targets Insights into the Structure, Function, and Regulation of Human Cytochrome P450 1A2
Current Drug Metabolism <i>Click</i> Reaction in the Synthesis of Dendrimer Drug-delivery Systems
Current Medicinal Chemistry The Association of Palmitoylethanolamide with Luteolin Decreases Neuroinflammation and Stimulates Autophagy in Parkinson's Disease Model
CNS & Neurological Disorders - Drug Targets Choosing between Targeted Therapies for Rheumatoid Arthritis Patients: The Oncology Perspective
Current Rheumatology Reviews Role of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) in Different Disease States: Recent Updates
Current Medicinal Chemistry Small Molecule Immunosuppressive Agents in Experimental and Clinical Transplantation
Current Drug Targets - Cardiovascular & Hematological Disorders Identification of Novel IRAK-4 Inhibitors Through Pharmacophore Modeling, Atom-based 3D-QSAR, Docking Strategies and Molecular Dynamics Simulation
Letters in Drug Design & Discovery Unusual Food Allergy: AlioideaAllergic Reactions Overview
Recent Patents on Inflammation & Allergy Drug Discovery Models to Study Atherosclerosis: A Mechanistic Insight
Current Vascular Pharmacology Enhanced Expression of miR-199b-5p Promotes Proliferation of Pancreatic β-Cells by Down-Regulation of MLK3
MicroRNA Anti-Inflammatory Drugs in Psychiatry
Inflammation & Allergy - Drug Targets (Discontinued) Recent Advances in Radiation Therapy of Cancer Cells: A Step towards an Experimental and Systems Biology Framework
Current Radiopharmaceuticals